Saxenda weight loss claims on TikTok: what 21 lbs in 5 weeks actually means
Quick answer
The creator is on liraglutide 3.0 mg (Saxenda), an FDA-approved GLP-1 receptor agonist for chronic weight management, having completed the standard titration schedule over five weeks. She reports 21 pounds of weight loss and constipation as a primary side effect, both of which are within the physiological range for this medication class, though the weight loss rate significantly exceeds clinical trial averages. Her plan to discontinue once she reaches a goal weight is a clinically relevant concern, as cessation of GLP-1 therapy is associated with significant weight regain in most patients.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @hairbylyndsayb actually say?
She reported losing 21 pounds in five weeks on Saxenda (liraglutide), said she just reached the maximum dose of 3.0 mg, and described constipation as her worst side effect. She also called Saxenda "a lot like Wegovy," which is a comparison worth examining carefully.
To her credit, she did not claim Saxenda cures anything, did not recommend a specific dose to viewers, and was upfront about her side effects. The core claims here are: (1) 21 pounds in five weeks is real, (2) 3.0 mg is the "full dosage," and (3) Saxenda and Wegovy are similar medications. Those are all checkable, and the answers are more complicated than her video suggests.
Does the science back this up?
Partly. The clinical data on liraglutide supports meaningful weight loss, but 21 pounds in five weeks is far above average, and the drug comparison she made is imprecise enough to mislead viewers who are shopping for their own treatment.
The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) found that patients on 3.0 mg liraglutide lost an average of 8.4 kg (about 18.5 lbs) over 56 weeks, not five. Losing 21 pounds in five weeks would require a caloric deficit far beyond what liraglutide alone typically produces. That does not mean she is lying. It means she may have significant water weight loss in the early weeks, possibly a stricter diet than she mentioned, or natural variation. But her results are statistical outliers, not the norm.
On the Saxenda-Wegovy comparison: liraglutide (Saxenda) and semaglutide (Wegovy) are both GLP-1 receptor agonists, but they are different molecules with different half-lives, dosing schedules, and efficacy profiles. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide produced roughly twice the weight loss of liraglutide in head-to-head comparisons. Calling them similar is a stretch.
What did they get wrong (or right)?
She got the side effect picture basically right. The dose framing needs a correction. And the Wegovy comparison is where she drifts into territory that could genuinely confuse people.
Constipation is real and well-documented with GLP-1 agonists. A 2022 systematic review (Zhao et al., Diabetes, Obesity and Metabolism) confirmed constipation affects 11-19% of liraglutide users, often requiring intervention. Her experience tracks with the data.
On dosing: she said "I'll be on this dosage forever." The 3.0 mg dose is the approved maintenance dose for weight management in Saxenda's label, not a stopping point or ceiling tied to a goal weight. Framing it as a finish line could mislead viewers into thinking they will eventually taper off, which is not how GLP-1 therapy typically works. Most patients who stop regain weight.
The Wegovy comparison is the biggest issue. Yes, both are GLP-1 agonists. But they are not interchangeable, not equivalent, and do not produce the same outcomes. Viewers who hear "it's a lot like Wegovy" may assume the results are the same or that one can substitute for the other. That is not supported by the evidence.
What should you actually know?
Saxenda is a legitimate, FDA-approved medication for chronic weight management. But early dramatic results are not the standard, and the comparison to Wegovy understates real differences between these drugs.
If you are considering Saxenda or any GLP-1 therapy, a few things matter more than a TikTok result. First, average weight loss on liraglutide 3.0 mg is roughly 5-8% of body weight over a year, not 21 pounds in a month. Second, weight regain after stopping is common, with studies showing patients regain two-thirds of lost weight within a year of discontinuation (Rubino et al., 2021, JAMA). Third, GLP-1 medications are not a short-term fix. The framing of "until I reach my goal" suggests she may plan to stop, which is a conversation she should be having with her prescriber, not announcing to TikTok.
- Saxenda requires a titration schedule to reach 3.0 mg, typically over 4-5 weeks, exactly as described.
- Constipation management during GLP-1 therapy is a legitimate clinical concern, not a minor inconvenience.
- Individual results vary significantly. Outlier cases like this one do not represent what most patients will experience.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Saxenda weight loss claims on TikTok: what 21 lbs in 5 weeks actually means, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Saxenda weight loss claims on TikTok: what 21 lbs in 5 weeks actually means is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator is on liraglutide 3.
FormBlends verdict
The creator is on liraglutide 3.0 mg (Saxenda), an FDA-approved GLP-1 receptor agonist for chronic weight management, having completed the standard titration schedule over five weeks. She reports 21 pounds of weight loss and constipation as a primary side effect, both of which are within the physiological range for this medication class, though the weight loss rate significantly exceeds clinical trial averages. Her plan to discontinue once she reaches a goal weight is a clinically relevant concern, as cessation of GLP-1 therapy is associated with significant weight regain in most patients.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is on liraglutide 3.0 mg (Saxenda), an FDA-approved GLP-1 receptor agonist for chronic weight management, having completed the standard titration schedule over five weeks. She reports 21 pounds of weight loss and constipation as a primary side effect, both of which are within the physiological range for this medication class, though the weight loss rate significantly exceeds clinical trial averages. Her plan to discontinue once she reaches a goal weight is a clinically relevant concern, as cessation of GLP-1 therapy is associated with significant weight regain in most patients.
- Average weight loss on liraglutide 3.0 mg in clinical trials is about 8.4 kg over 56 weeks (Pi-Sunyer et al., 2015, NEJM), not 21 pounds in 5 weeks.
- Saxenda and Wegovy are both GLP-1 agonists but are not the same drug. Semaglutide produces roughly twice the weight loss of liraglutide in comparative studies (Wilding et al., 2021, NEJM).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Average weight loss on liraglutide 3.0 mg in clinical trials is about 8.4 kg over 56 weeks (Pi-Sunyer et al., 2015, NEJM), not 21 pounds in 5 weeks.
- Saxenda and Wegovy are both GLP-1 agonists but are not the same drug. Semaglutide produces roughly twice the weight loss of liraglutide in comparative studies (Wilding et al., 2021, NEJM).
- Constipation affects 11-19% of liraglutide users and often requires active management, as confirmed by Zhao et al. (2022, Diabetes, Obesity and Metabolism).
- Stopping GLP-1 therapy after hitting a goal weight typically leads to regaining about two-thirds of lost weight within 12 months (Rubino et al., 2021, JAMA).
- Early weight loss on GLP-1 medications often includes water weight and gut motility changes, which can inflate short-term numbers beyond what fat loss alone would explain.
- The standard Saxenda titration to 3.0 mg takes 4-5 weeks, consistent with what the creator described, and is designed to reduce gastrointestinal side effects.
- Individual results on GLP-1 medications vary widely. Social media cases showing dramatic early results are not representative of typical patient outcomes and should not be used to set expectations.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
LyndsayB · TikTok creator
52.6K views on this video
Late post from Dec 16th and week 5 on Saxenda. Down 21 pounds! #saxenda #wls #fypシ #fyp #fyppppppppppppppppppppppp #weightloss #weightlossprogress #weightlossmotivation #saxendaweightlossjourney #saxendajourney #week5 #latepost #necklift
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by LyndsayB, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.